In conclusion, we suggest that BubR1 is a reliable prognostic marker for predicting RFS after initial treatment, and that assessing the levels of BubR1 in early-stage ovarian cancer patients, especially with FIGO I stage, can influence the choice of adequate treatment for ovarian cancers. Here, BUB1B is linked to ovarian cancer.